To study the tumor targeting efficacy and MOA of Allo/U15BCAR-NKT cells, we utilized the BCMA+ human MM cell line, MM.1S, which was genetically modified to express FG for luciferase assay and flow cytometry monitoring (denoted as MM.1S-FG) (Figure 4A). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.